In this issue

News that two notable Covid-19 vaccine candidates had demonstrated 90% or greater efficacy in clinical trials has been music to the ears of many. The idea that the medical, financial and social impact of the pandemic may soon come to an end is a very welcome notion but, unfortunately, getting a vaccine from the lab, to market and then most importantly to the patients that need it – well, that’s a very complicated process.

With that in mind, we take a deep dive into the vaccine supply chain to find out what it will take to deliver a vaccine to patients around the world, as well as the hurdles that may stand in the way of a speedy distribution.

Before a vaccine even hits the market, it has to undergo Phase III trials. But what does that actually mean? We review the Phase III trial process to learn what goes into this ‘gold standard’ of testing.

Switching gears, we examine vaccine research in HIV to find out why a preventative vaccine has so far eluded researchers despite ground-breaking treatment innovation in the sector, find out what makes yeast a promising solution to supply chain vulnerabilities in plant-based drug ingredients, and investigate cancer treatment disparities across Europe.

All this and more in this latest issue of Pharma Technology Magazine.

Stay safe.

Eloise Mclennan, editor